These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26123049)

  • 1. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
    Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Antihypertensive Drugs in Neoplastic Patients.
    Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
    High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
    Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
    Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
    Kruzliak P; Novák J; Novák M
    Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular toxicity associated with anti-angiogenic drugs.
    Neves KB; Montezano AC; Lang NN; Touyz RM
    Clin Sci (Lond); 2020 Sep; 134(18):2503-2520. PubMed ID: 32990313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.
    Small HY; Montezano AC; Rios FJ; Savoia C; Touyz RM
    Can J Cardiol; 2014 May; 30(5):534-43. PubMed ID: 24786444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncontrolled Hypertension and Oncology: Clinical Tips.
    Kalaitzidis RG; Elisaf MS
    Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
    Faruque LI; Lin M; Battistella M; Wiebe N; Reiman T; Hemmelgarn B; Thomas C; Tonelli M
    PLoS One; 2014; 9(7):e101145. PubMed ID: 24988441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of hypertension in angiogenesis inhibitor-treated patients.
    Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
    Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
    Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
    Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension as a surrogate marker for the activity of anti-VEGF agents.
    Mir O; Ropert S; Alexandre J; Goldwasser F
    Ann Oncol; 2009 May; 20(5):967-70. PubMed ID: 19403940
    [No Abstract]   [Full Text] [Related]  

  • 12. Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury.
    Neves KB; Rios FJ; Jones R; Evans TRJ; Montezano AC; Touyz RM
    Cardiovasc Res; 2019 Apr; 115(5):978-988. PubMed ID: 30753341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF kinase inhibitors: how do they cause hypertension?
    Bhargava P
    Am J Physiol Regul Integr Comp Physiol; 2009 Jul; 297(1):R1-5. PubMed ID: 19439616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.
    Thanigaimani S; Kichenadasse G; Mangoni AA
    Curr Vasc Pharmacol; 2011 May; 9(3):358-80. PubMed ID: 20807189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
    Isobe T; Komatsu R; Honda M; Kuramoto S; Shindoh H; Tabo M
    J Toxicol Sci; 2014 Apr; 39(2):237-42. PubMed ID: 24646704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF therapies in the clinic.
    Meadows KL; Hurwitz HI
    Cold Spring Harb Perspect Med; 2012 Oct; 2(10):. PubMed ID: 23028128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
    Robinson ES; Khankin EV; Karumanchi SA; Humphreys BD
    Semin Nephrol; 2010 Nov; 30(6):591-601. PubMed ID: 21146124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.